Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023627 · ClinicalTrials.gov registry record · Phase 2
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Phase 2 study of Ovarian Cancer, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT07023627: Recruiting Phase 2 study of Ovarian Cancer, sponsored by Incyte Corporation.
NCT07023627 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 160 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07023627, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Primary Outcome
Defined as having a confirmed best overall response of complete response (CR) or partial response (PR), as determined by independent review committee (IRC) assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Conditions Studied
Interventions
- DRUG INCB123667
Study Locations (20)
Florida
- Florida Cancer Specialists & Research Institute - Fort Myers
- Sylvester Comprehensive Cancer Center - Miami
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Florida Cancer Specialists & Research Institute - West Palm Beach
California
- University of California, Los Angeles Medical Center - Los Angeles
- Scripps Healthscripps Mercy Hospital Prebys Cancer Center - San Diego
Maryland
- Greater Baltimore Medical Center - Baltimore
- John Hopkins University-School of Medicine - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
- Umass Memorial Medical Center, Inc. - Worcester
Alabama
- Usa Health Mitchell Cancer Institute - Mobile
Arkansas
- Uams Winthrop P Rockefeller Cancer Institute - Little Rock
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Georgia
- Northeast Georgia Medical Center Gainesville - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2027-10-24 |
| Phase | Phase 2 |
What NCT07023627 shows while recruiting
NCT07023627 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which INCB123667 is the first listed.
NCT07023627 names 20 study sites across 14 states, led by Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT07023627 about?
NCT07023627 is a clinical study titled "A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression". This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
What is the current status of trial NCT07023627?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-11-12. Estimated completion is 2027-10-24.
What conditions does trial NCT07023627 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT07023627?
The interventions under investigation include: INCB123667 (DRUG).
Who is sponsoring clinical trial NCT07023627?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07023627 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07023627's enrollment target sits among peer trials
160 117th of 322 higher than 206 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI